New diabetes drug tirzepatide tested in chinese patients

NCT ID NCT05963022

Completed Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tested the drug tirzepatide (a once-weekly injection) against a placebo in 206 Chinese adults with type 2 diabetes. The goal was to see if tirzepatide could safely lower blood sugar levels. Participants had to have stable weight and a BMI of 23 or higher. The study is now complete, and results will show how well tirzepatide works for this population.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tirzepatide (a once-weekly injection)
What this could lead to: If successful, tirzepatide could offer a new, effective option for managing blood sugar in Chinese patients with type 2 diabetes.
What could go wrong: This is a completed Phase 3 trial, but results are not yet published. Tirzepatide may cause side effects like nausea or diarrhea, and it is not a cure—patients will need ongoing treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES

Contacts and locations

Show contact details

Locations

Affiliated Hospital of Jiangsu University

Zhenjiang, Jiangsu, 212000, China
Chengdu Fifth People's Hospital

Chengdu, Sichuan, 611130, China
Chinese PLA General Hospital

Beijing, Beijing Municipality, 100853, China
Dalian Municipal Central Hospital Affiliated of Dalian Medical University

Dalian, Liaoning, 116033, China
Dalian University - The Affiliated Zhongshan Hospital

Dalian, Liaoning, 116001, China
Hainan General Hospital

Haikou, Hainan, 570311, China
Huizhou Municipal Central Hospital

Huizhou, Guangdong, 516001, China
Huzhou Central Hospital

Huzhou, Zhejiang, 313000, China
Jiading District Central Hospital

Shanghai, Shanghai Municipality, 201800, China
Jiangxi Pingxiang People's Hospital

Pingxiang, Jiangxi, 337055, China
Jinan Central Hospital

Jinan, Shandong, 250013, China
Nanjing First Hospital

Nanjing, Jiangsu, 210012, China
Nanjing Medical University - Nanjing Jiangning Hospital

Nanjing, Jiangsu, 211100, China
Panjin Liaoyou Baoshihua Hospital

Liaoyou, Liaoning, 124009, China
Pudong New Area People's Hospital Shanghai

Shanghai, Shanghai Municipality, 201200, China
Shunde Hospital of Southern Medical Univesity

Foshan, Guangdong, 528399, China
The First Affiliated Hospital of Henan University of Science &Technology

Luoyang Shi, Henan, 471003, China
The First Affiliated Hospital of Nanyang Medical College

Nanyang, Henan, 473007, China
The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, 215006, China
The First Affiliated Hospital of Xi'an Medical University

Xi'an, Shaanxi, 710077, China
The First People's Hospital of Changde City

Changde, Hunan, 415003, China
The Fourth Affiliated Hospital of Harbin Medical University

Harbin, Heilongjiang, 150001, China
The Second Affiliated Hospital of Nanjing Medical University

Nanjing, Jiangsu, 210011, China
The Second Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, 450014, China
Tianjin Medical University General Hospital

Tianjin, Tianjin Municipality, 300052, China
West China Hospital of Sichuan University

Chengdu, Sichuan, 610041, China
Yichang Central People's Hospital

Yichang, Hubei, 443003, China
Zunyi First People's Hospital

Zunyi, Guizhou, 563002, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.